about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesMagnesium inhibits spontaneous and iron-induced aggregation of alpha-synucleinEffect of natural exogenous antioxidants on aging and on neurodegenerative diseasesAbnormal brain iron homeostasis in human and animal prion disordersAlpha-synuclein is a cellular ferrireductase.Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregatesIron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms?Late-life hemoglobin and the incidence of Parkinson's disease.The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expressionOxidative stress and NAD+ in ischemic brain injury: current advances and future perspectives.Dopamine D₂/D₃ agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease.Molecular control of vertebrate iron homeostasis by iron regulatory proteinsAssessing of plasma levels of iron, zinc and copper in Iranian Parkinson's disease.A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD.Meta-analysis of brain iron levels of Parkinson's disease patients determined by postmortem and MRI measurements.Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases.Review: iron metabolism and the role of iron in neurodegenerative disorders.Alterations in the basal ganglia in patients with brain tumours may be due to excessive iron deposition.Transcriptional modulation in a leukocyte-depleted splenic cell population during prion disease.High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease.
P2860
Q24289511-DF707E8A-95AB-4F2B-9317-C1BAF3B08226Q24292317-BF86D70A-5009-43F2-BD1E-97AA18C22FFAQ28289119-313FBD9A-6FEF-428B-893C-EF20ECDFBBB2Q33417668-16179733-DBB6-4280-A04E-1BDFF63E2452Q33798034-A359C292-1216-4EDD-9286-F8D583264BCFQ34074933-9CFA9FC9-1BBA-4628-AD1D-5FF096675DDAQ34109492-20027FB3-02B8-4094-A0D4-00C36BAF5951Q34427716-142062A8-5AEF-4AC5-9F5C-325780CD1AB0Q36012226-2661A35B-5E2A-4B53-8182-250A22206251Q36090617-050BD92C-CE5E-483E-B997-2A08E24CF9D2Q36382848-03B1384E-A804-499F-A613-B4F7B97C44DCQ36536936-85D09969-62F1-44A4-BF3B-C859A0579A15Q36750001-92138E1D-2F5C-4C76-8493-419FC9FABC36Q37258755-7206F199-C4BD-4D75-B392-712D34622579Q37402514-75D39654-F8AB-4117-BA41-138D2C2CEB46Q37922607-7E2838E5-14EF-49AC-A172-7F6214E0E1BEQ38155941-6A06BA68-56B3-4929-A857-7534C0350361Q42469086-26D9251D-66B4-40B6-A5A2-FDD283F66CE2Q43614738-05587259-1A72-43F6-9E80-7907EA2B8768Q48851886-EC5715F9-394F-4A4A-892C-ACED1DDFEE01
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Iron and Parkinson's disease.
@ast
Iron and Parkinson's disease.
@en
Iron and Parkinson's disease.
@nl
type
label
Iron and Parkinson's disease.
@ast
Iron and Parkinson's disease.
@en
Iron and Parkinson's disease.
@nl
prefLabel
Iron and Parkinson's disease.
@ast
Iron and Parkinson's disease.
@en
Iron and Parkinson's disease.
@nl
P2860
P1433
P1476
Iron and Parkinson's disease.
@en
P2093
Benjamin Wolozin
Natalie Golts
P2860
P356
10.1177/107385840200800107
P577
2002-02-01T00:00:00Z